DK1734987T3 - Interferon-beta til antivirusbehandling af respiratoriske sygdomme - Google Patents

Interferon-beta til antivirusbehandling af respiratoriske sygdomme

Info

Publication number
DK1734987T3
DK1734987T3 DK05708482.4T DK05708482T DK1734987T3 DK 1734987 T3 DK1734987 T3 DK 1734987T3 DK 05708482 T DK05708482 T DK 05708482T DK 1734987 T3 DK1734987 T3 DK 1734987T3
Authority
DK
Denmark
Prior art keywords
agent
interferon beta
respiratory diseases
treatment
virus treatment
Prior art date
Application number
DK05708482.4T
Other languages
English (en)
Inventor
Donna Elizabeth Davies
Peter Alexander Blanch Wark
Stephen Holgate
Sebastian L Johnston
Original Assignee
Univ Southampton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southampton filed Critical Univ Southampton
Application granted granted Critical
Publication of DK1734987T3 publication Critical patent/DK1734987T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DK05708482.4T 2004-03-12 2005-03-07 Interferon-beta til antivirusbehandling af respiratoriske sygdomme DK1734987T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0405634.7A GB0405634D0 (en) 2004-03-12 2004-03-12 Anti-virus therapy for respiratory diseases
PCT/GB2005/050031 WO2005087253A2 (en) 2004-03-12 2005-03-07 Interferon-beta for anti-virus therapy for respiratory diseases

Publications (1)

Publication Number Publication Date
DK1734987T3 true DK1734987T3 (da) 2010-08-30

Family

ID=32117582

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05708482.4T DK1734987T3 (da) 2004-03-12 2005-03-07 Interferon-beta til antivirusbehandling af respiratoriske sygdomme

Country Status (13)

Country Link
US (3) US7569216B2 (da)
EP (2) EP2206512A3 (da)
JP (2) JP4807526B2 (da)
AT (1) ATE466591T1 (da)
CA (2) CA2558212C (da)
DE (1) DE602005021078D1 (da)
DK (1) DK1734987T3 (da)
ES (1) ES2343732T3 (da)
GB (1) GB0405634D0 (da)
HK (1) HK1097181A1 (da)
PL (1) PL1734987T3 (da)
PT (1) PT1734987E (da)
WO (1) WO2005087253A2 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
US8318423B2 (en) * 2004-07-06 2012-11-27 Focus Diagnostics, Inc. Methods and compositions for detecting rhinoviruses
EP1922081B1 (en) * 2005-09-09 2012-08-15 Imperial Innovations Limited Interferon lambda therapy for treatment of respiratory diseases
CA2622987C (en) 2005-09-20 2018-02-27 New York University Method of treating pulmonary disease with interferons
DE102006022877B4 (de) 2006-05-15 2009-01-29 Sartorius Stedim Biotech Gmbh Verfahren zur Bestimmung der Viabilität von Zellen in Zellkulturen
US7871603B2 (en) 2007-05-18 2011-01-18 Synairgen Research Limited Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly
GB0713402D0 (en) * 2007-07-11 2007-08-22 Cardiff & Vale Nhs Trust A method of diagnosing a condition using a neural network
JP2011506396A (ja) * 2007-12-13 2011-03-03 グラクソ グループ リミテッド 肺送達用組成物
US20110236349A1 (en) * 2008-12-19 2011-09-29 Koff Jonathan L Use of Epidermal Growth Factor Inhibitors in the Treatment of Viral Infection
CA2782512A1 (en) * 2009-12-02 2011-06-09 Neetour Medical Ltd. Hemodynamics-based monitoring and evaluation of a respiratory condition
RS55154B1 (sr) 2010-03-12 2017-01-31 Synairgen Res Ltd Interferon beta za upotrebu u lečenju bolesti donjeg respiratornog trakta uzrokovane gripom
PL2618842T3 (pl) 2010-09-22 2019-10-31 Ena Therapeutics Pty Ltd Nowa metoda immunostymulacyjna
CN104968673B (zh) 2014-01-08 2018-11-02 德益阳光生物技术（北京）有限责任公司 融合多肽及使用方法
WO2019023196A1 (en) * 2017-07-24 2019-01-31 Novavax, Inc. METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASE
EP3923975A4 (en) * 2019-02-13 2023-04-19 University of Florida Research Foundation, Inc. TARGETING A LUNG-RESIDENT TNFR2+ CDC2 (R2D2) SUBPOPULATION TO TREAT ASTHMA
WO2020257870A1 (en) 2019-06-26 2020-12-30 Ena Therapeutics Pty Ltd Novel molecules
JP2023535710A (ja) 2020-07-20 2023-08-21 シナーゲン リサーチ リミテッド ＳＡＲＳ－ＣｏＶ－２感染患者におけるアウトカムを改善するための吸入インターフェロン－ベータ
GB202014114D0 (en) 2020-09-08 2020-10-21 Synairgen Res Ltd Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid
CN117729930A (zh) * 2020-11-04 2024-03-19 埃泽瑞斯公司 IFN-λ mRNA治疗病毒感染的用途
EP4292604A1 (en) * 2021-01-13 2023-12-20 Abion Inc. Prophylactic administration method against respiratory virus, comprising administering interferon-beta to potential respiratory virus-infected subject

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596260B1 (en) * 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
CA2190502A1 (en) * 1994-05-18 1995-11-23 Robert M. Platz Methods and compositions for the dry powder formulation of interferons
US6030609A (en) 1995-05-19 2000-02-29 Case Western Reserve University Method and composition for treating paramyxovirus
US20010031253A1 (en) * 1996-07-24 2001-10-18 Gruenberg Micheal L. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
AU780270B2 (en) * 2000-02-23 2005-03-10 Association Francaise Contre Les Myopathies Treatment of immune diseases
GB2362884A (en) 2000-05-30 2001-12-05 Isis Innovation Extended duration of airway gene therapy
AU2002212107A1 (en) 2000-11-02 2002-05-15 Maxygen Aps New multimeric interferon beta polypeptides
AU2002254174A1 (en) * 2001-03-13 2002-09-24 Vical Incorporated Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
AU2003215136A1 (en) 2002-02-08 2003-09-02 University Of Medicine And Dentistry Of New Jersey Ifn-a/b-independent mechanism of antiviral protection
US20040037809A1 (en) * 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
JP2006509041A (ja) 2002-10-23 2006-03-16 ザイモジェネティクス，インコーポレイティド Ｉｌ−２８およびｉｌ−２９を用いるウイルス感染を治療するための方法
DK1668031T3 (da) 2003-08-07 2008-06-30 Zymogenetics Inc Homogene præparater af IL-29
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
US20050244423A1 (en) 2004-04-02 2005-11-03 Klucher Kevin M Methods for treating viral infection using IL-28 and IL-29 cysteine mutants

Also Published As

Publication number Publication date
US20130209399A1 (en) 2013-08-15
PL1734987T3 (pl) 2010-10-29
CA2558212A1 (en) 2005-09-22
JP2011144201A (ja) 2011-07-28
US20090257980A1 (en) 2009-10-15
JP4807526B2 (ja) 2011-11-02
EP2206512A3 (en) 2013-01-09
WO2005087253A3 (en) 2005-11-24
US8273342B2 (en) 2012-09-25
CA2558212C (en) 2012-11-27
EP1734987A2 (en) 2006-12-27
EP1734987B1 (en) 2010-05-05
ATE466591T1 (de) 2010-05-15
WO2005087253A2 (en) 2005-09-22
CA2787978A1 (en) 2005-09-22
DE602005021078D1 (de) 2010-06-17
GB0405634D0 (en) 2004-04-21
EP2206512A2 (en) 2010-07-14
ES2343732T3 (es) 2010-08-09
US9089535B2 (en) 2015-07-28
US7569216B2 (en) 2009-08-04
JP2007528890A (ja) 2007-10-18
PT1734987E (pt) 2010-07-06
US20070134763A1 (en) 2007-06-14
HK1097181A1 (en) 2007-06-22

Similar Documents

Publication Publication Date Title
DK1734987T3 (da) Interferon-beta til antivirusbehandling af respiratoriske sygdomme
DE602005007708D1 (de) Neue kombination von anticholinergen und beta mimetika zur behanldung von atemwegserkrankungen
DE602005026007D1 (de) Opioide zur behandlung von chronisch-obstruktiver lungenerkrankung (copd)
WO2008149148A3 (en) Polypeptides, antibody variable domains and antagonists
WO2008149144A3 (en) Polypeptides, antibody variable domains and antagonists
ATE421325T1 (de) Kombination von methylxanthinverbindungen und steroiden zur behandlung chronischer atemwegserkrankungen
WO2006086107A3 (en) Methods and compositions for minimizing accrual of inhalable insulin in the lungs
NO20070651L (no) Sammensetninger av statiner med bronkodilatorer
TW200720236A (en) Organic compounds
UA83813C2 (ru) Порошковое лекарственное средство, которое содержит соль тиотропия и ксинафоат салметерола
UY28596A1 (es) Nuevo anhidrato cristalino con accion anticolinergica
WO2007029041A3 (en) Interferon lambda therapy for treatment of respiratory diseases
IL199022A0 (en) A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (copd) and asthma
CY1108420T1 (el) Προτοτυπο τιοτροπιουχο κονιωδες σκευασμα για εισπνοη
NO20073909L (no) Forstover-formulering
RS20060292A (en) Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same
NO20062384L (no) Anvendelse av BH4 for bahandling av respiratoriske sykdommer
Tiwari et al. C71 YOU ARE WHAT YOU BREATHE: AIRWAY CELL BIOLOGY IN COPD: P53-And Pai-1-Mediated Induction Of CXC Chemokines And Cxcr2: Importance In Pulmonary Inflammation Due To Cigarette Smoke Exposure
EP4196091A4 (en) USE OF A HEPARIN COMPOSITION FOR THE TREATMENT OF VIRAL LUNG DISEASES, ACUTE AND/OR CHRONIC LUNG DISEASES
ZA200801408B (en) A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (COPD) and asthma
ZA200801407B (en) A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (COPD) and asthma